文献速递心血管MR

应用晚期钆增强与细胞外容积心脏磁共振预测肥厚型心肌病患者5年心脏性猝死风险及晕厥或非持续性室性心动过速

Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
PubMed 文献 · Eur Radiol · 2017-06-14

研究纳入73例肥厚型心肌病患者和16例对照,行1.5-T心脏磁共振,采用3SD、5SD及半高全宽法量化晚期钆增强,并用3(3)5改良Look-Locker反转恢复序列生成T1与细胞外容积图。结果显示全局细胞外容积是预测心脏性猝死风险≥4%的最佳参数(AUC 0.83),优于各晚期钆增强量化法;将心脏性猝死风险评分与全局细胞外容积联合使用可提高识别晕厥或非持续性室性心动过速的诊断准确率。

要点

  • 全局细胞外容积预测心脏性猝死风险≥4%的AUC为0.83,优于3SD、5SD及半高全宽法晚期钆增强(AUC分别为0.68、0.70、0.70,均P<0.05)。
  • 心脏性猝死风险评分联合全局细胞外容积可提高识别晕厥或非持续性室性心动过速的诊断准确率。
  • 联合使用可能改善肥厚型心肌病患者植入式心律转复除颤器的选择。

核心结论

  • 心脏性猝死风险评分联合全局细胞外容积有潜力改善肥厚型心肌病患者的选择,使植入式心律转复除颤器获益最大。

研究设计与样本

  • 在73例肥厚型心肌病患者和16例对照中行1.5-T心脏磁共振,采用3SD、5SD及半高全宽法量化晚期钆增强,并用3(3)5改良Look-Locker反转恢复序列生成T1与细胞外容积图,以受试者工作特征曲线分析评估参数。

诊断标准与关键数值

  • 全局细胞外容积预测心脏性猝死风险≥4%的AUC为0.83;3SD法晚期钆增强AUC为0.68、5SD法为0.70、半高全宽法为0.70(均P<0.05,均劣于全局细胞外容积)。

临床应用与阅片要点

  • 全局细胞外容积是识别心脏性猝死风险≥4%的肥厚型心肌病患者的最佳参数;心脏性猝死风险评分联合全局细胞外容积可提高识别晕厥或非持续性室性心动过速的诊断准确率,可能改善植入式心律转复除颤器的患者选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the ability of late gadolinium enhancement (LGE) and mapping cardiac magnetic resonance (CMR) including native T1 and global extracellular volume (ECV) to identify hypertrophic cardiomyopathy (HCM) patients at risk for sudden cardiac death (SCD) and to predict syncope or non-sustained ventricular tachycardia (VT).

METHODS: A 1.5-T CMR was performed in 73 HCM patients and 16 controls. LGE size was quantified using the 3SD, 5SD and full width at half maximum (FWHM) method. T1 and ECV maps were generated by a 3(3)5 modified Look-Locker inversion recovery sequence. Receiver-operating curve analysis evaluated the best parameter to identify patients with increased SCD risk ≥4% and patients with syncope or non-sustained VT.

RESULTS: Global ECV was the best predictor of SCD risk with an area under the curve (AUC) of 0.83. LGE size was significantly inferior to global ECV with an AUC of 0.68, 0.70 and 0.70 (all P < 0.05) for 3SD-, 5SD- and FWHM-LGE, respectively. Combined use of the SCD risk score and global ECV significantly improved the diagnostic accuracy to identify HCM patients with syncope or non-sustained VT.

CONCLUSIONS: Combined use of the SCD risk score and global ECV has the potential to improve HCM patient selection, benefiting most implantable cardioverter defibrillators.

KEY POINTS: • Global ECV identified the best HCM patients with increased SCD risk. • Global ECV performed equally well compared to a SCD risk score. • Combined use of the SCD risk score and global ECV improved test accuracy. • Combined use potentially improves selection of HCM patients for ICD implantation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Avanesov M, Münch J, Weinrich J, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol. 2017. PMID: 28616729. doi:10.1007/s00330-017-4869-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。